血漿タンパク質治療薬の世界市場：洞察、競合情勢、市場予測：2030年

血漿タンパク質治療薬の市場規模は、2023年に250億7,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に6.65％のCAGRで拡大し、2030年には392億7,000万米ドルに達すると予測されています。血漿タンパク質治療薬が血友病、多発性硬化症、免疫性血小板減少症などの多様な疾患の管理において、必須凝固因子の供給、免疫反応の調節、患者の転帰の改善など、重要な役割を果たしているため、血漿タンパク質治療薬市場は大きく成長しています。これらの治療法における継続的な進歩と用途の拡大は、2024年から2030年までの予測期間中に同市場の大幅な成長を促進すると予想されます。

世界血友病連盟（2022年）の報告によると、世界では毎年約2万人の血友病患者が誕生しており、そのうち約7,000人が重症に分類されています。これに加え、血友病患者は23万3,577人で、その内訳は血友病Aが18万5,318人、血友病Bが3万7,998人であるとしています。

世界保健機関（WHO）のデータ（2023年）によると、世界で180万人以上が多発性硬化症（MS）に罹患していると報告されています。多発性硬化症は、認知、感情、運動、感覚、視覚など様々な機能に影響を及ぼします。MSの治療では、血漿蛋白療法、特に免疫グロブリン静注療法（IVIG）が免疫系を調節し炎症を抑えるために使用されます。IVIGは、神経周囲のミエリン鞘を攻撃する自己免疫反応を抑制し、再発頻度と重症度を低下させる可能性があります。

免疫性血小板減少症（ITP）は、生後3カ月から100歳以上まで、あらゆる年齢層の人が罹患する可能性があると、2022年の全米希少疾患機構は述べています。ITPと診断された患者の約40％は10歳未満の小児です。世界全体では、20万人以上がこの疾患に罹患していると推定されています。血漿蛋白療法、特に免疫グロブリン静注療法（IVIG）は、血小板数を増加させ、免疫介在性血小板破壊を減少させるために使用されます。IVIGは、免疫系を調節するためにプールされた抗体を提供することによって機能し、血小板レベルを迅速に改善し出血を予防するために、急性または重症の症例に通常使用されます。

したがって、上記のすべての要因が総合的に、2024年から2030年までの予測期間中、血漿タンパク質治療薬市場全体を牽引することになります。

当レポートでは、世界の血漿タンパク質治療薬市場について調査し、市場の概要とともに、製品別、用途別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 血漿タンパク質治療薬市場レポートのイントロダクション

第2章 血漿タンパク質治療薬市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 血漿タンパク質治療薬市場の主な要因分析

• 血漿タンパク質治療薬の市場促進要因
• 血漿タンパク質治療薬の市場抑制要因と課題
• 血漿タンパク質治療薬の市場機会

第6章 血漿タンパク質治療薬市場におけるポーターのファイブフォース分析

第7章 血漿タンパク質治療薬市場の評価

• 製品別
  • 免疫グロブリン
  • アルブミン
  • 血漿由来因子VIII
  • その他
• 用途別
  • 血友病
  • 特発性血小板減少症
  • 原発性免疫不全症
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 血漿タンパク質治療薬市場の企業と製品プロファイル

• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Biotest AG
• Grifols, S.A.
• CSL
• Bayer AG
• Baxter
• Biologics, Inc.
• Bio Products Laboratory Ltd
• Kedrion S.p.A
• China Biologic Products Holdings, Inc

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Plasma Protein Therapeutics Market in Global (2021-2030)
• Table 3: Plasma Protein Therapeutics Market in Global by Product (2021-2030)
• Table 4: Plasma Protein Therapeutics Market in Global by Application (2021-2030)
• Table 5: Plasma Protein Therapeutics Market in Global by Geography (2021-2030)
• Table 6: Plasma Protein Therapeutics Market in North America (2021-2030)
• Table 7: Plasma Protein Therapeutics Market in the United States (2021-2030)
• Table 8: Plasma Protein Therapeutics Market in Canada (2021-2030)
• Table 9: Plasma Protein Therapeutics Market in Mexico (2021-2030)
• Table 10: Plasma Protein Therapeutics Market in Europe (2021-2030)
• Table 11: Plasma Protein Therapeutics Market in France (2021-2030)
• Table 12: Plasma Protein Therapeutics Market in Germany (2021-2030)
• Table 13: Plasma Protein Therapeutics Market in United Kingdom (2021-2030)
• Table 14: Plasma Protein Therapeutics Market in Italy (2021-2030)
• Table 15: Plasma Protein Therapeutics Market in Spain (2021-2030)
• Table 16: Plasma Protein Therapeutics Market in the Rest of Europe (2021-2030)
• Table 17: Plasma Protein Therapeutics Market in Asia-Pacific (2021-2030)
• Table 18: Plasma Protein Therapeutics Market in China (2021-2030)
• Table 19: Plasma Protein Therapeutics Market in Japan (2021-2030)
• Table 20: Plasma Protein Therapeutics Market in India (2021-2030)
• Table 21: Plasma Protein Therapeutics Market in Australia (2021-2030)
• Table 22: Plasma Protein Therapeutics Market in South Korea (2021-2030)
• Table 23: Plasma Protein Therapeutics Market in Rest of Asia-Pacific (2021-2030)
• Table 24: Plasma Protein Therapeutics Market in the Rest of the World (2021-2030)
• Table 25: Plasma Protein Therapeutics Market in the Middle East (2021-2030)
• Table 26: Plasma Protein Therapeutics Market in Africa (2021-2030)
• Table 27: Plasma Protein Therapeutics Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Plasma Protein Therapeutics Market in Global (2021-2030)
• Figure 3: Plasma Protein Therapeutics Market in Global by Product (2021-2030)
• Figure 4: Plasma Protein Therapeutics Market in Global by Application (2021-2030)
• Figure 5: Plasma Protein Therapeutics Market in Global by Geography (2021-2030)
• Figure 6: Plasma Protein Therapeutics Market in North America (2021-2030)
• Figure 7: Plasma Protein Therapeutics Market in the United States (2021-2030)
• Figure 8: Plasma Protein Therapeutics Market in Canada (2021-2030)
• Figure 9: Plasma Protein Therapeutics Market in Mexico (2021-2030)
• Figure 10: Plasma Protein Therapeutics Market in Europe (2021-2030)
• Figure 11: Plasma Protein Therapeutics Market in France (2021-2030)
• Figure 12: Plasma Protein Therapeutics Market in Germany (2021-2030)
• Figure 13: Plasma Protein Therapeutics Market in United Kingdom (2021-2030)
• Figure 14: Plasma Protein Therapeutics Market in Italy (2021-2030)
• Figure 15: Plasma Protein Therapeutics Market in Spain (2021-2030)
• Figure 16: Plasma Protein Therapeutics Market in the Rest of Europe (2021-2030)
• Figure 17: Plasma Protein Therapeutics Market in Asia-Pacific (2021-2030)
• Figure 18: Plasma Protein Therapeutics Market in China (2021-2030)
• Figure 19: Plasma Protein Therapeutics Market in Japan (2021-2030)
• Figure 20: Plasma Protein Therapeutics Market in India (2021-2030)
• Figure 21: Plasma Protein Therapeutics Market in Australia (2021-2030)
• Figure 22: Plasma Protein Therapeutics Market in South Korea (2021-2030)
• Figure 23: Plasma Protein Therapeutics Market in Rest of Asia-Pacific (2021-2030)
• Figure 24: Plasma Protein Therapeutics Market in the Rest of the World (2021-2030)
• Figure 25: Plasma Protein Therapeutics Market in the Middle East (2021-2030)
• Figure 26: Plasma Protein Therapeutics Market in Africa (2021-2030)
• Figure 27: Plasma Protein Therapeutics Market in South America (2021-2030)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Marker Opportunities
• Figure 31: PORTER'S Five Force Analysis

Plasma Protein Therapeutics Market by Product (Immunoglobulin, Albumin, Plasma Derived Factor VIII, and Others), Application (Hemophilia, Idiopathic Thrombocytopenic, Primary Immunodeficiencies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the rising cases of autoimmune & neurological disorders and the increasing product developmental activities across the globe.

The plasma protein therapeutics market was valued at USD 25.07 billion in 2023, growing at a CAGR of 6.65% during the forecast period from 2024 to 2030 to reach USD 39.27 billion by 2030. The plasma protein therapeutics market is growing significantly due to the critical role plasma protein therapeutics play in managing diverse conditions such as hemophilia, multiple sclerosis, and immune thrombocytopenia by providing essential clotting factors, modulating immune responses, and improving patient outcomes. The ongoing advancements in these therapies and their expanding applications are expected to drive significant growth in the plasma protein therapeutics market during the forecast period from 2024 to 2030.

Plasma Protein Therapeutics Market Dynamics:

According to the World Federation of Haemophilia (2022) reports, approximately 20,000 people with hemophilia are born each year worldwide, with about 7,000 of these cases being classified as severe. In addition to this, the source further stated that there are 233,577 individuals with hemophilia, comprising 185,318 with Hemophilia A and 37,998 with Hemophilia B.

The report also highlighted the global distribution of factor VIII utilization globally, with Africa at 17%, Americas at 17%, Europe at 10%, South East Asia at 36%, Eastern Mediterranean at 11%, and Western Pacific at 9%. Plasma protein therapies, especially factor VIII, are crucial for managing hemophilia worldwide. In regions like Africa, the Americas, South East Asia, Europe, the Eastern Mediterranean, and the Western Pacific, these therapies provide essential clotting factors for treating hemophilia A and B, preventing and managing bleeding episodes, and ensuring effective disease management.

As per data from the World Health Organization (2023), it was reported that over 1.8 million people worldwide are affected by Multiple sclerosis (MS). It impacts various functions including cognitive, emotional, motor, sensory, and visual abilities. In the treatment of MS, plasma protein therapy, particularly intravenous immunoglobulin (IVIG), is used to modulate the immune system and reduce inflammation. IVIG helps to suppress the autoimmune response attacking the myelin sheath around nerves, potentially reducing relapse frequency and severity.

The National Organization for Rare Disorders in 2022, stated that immune thrombocytopenia (ITP) can affect individuals of all ages, ranging from as young as 3 months to over 100 years old. Approximately 40% of those diagnosed with ITP are children under the age of 10. Globally, it is estimated that more than 200,000 people are affected by this condition. Plasma protein therapy, specifically intravenous immunoglobulin (IVIG), is used to increase platelet counts and reduce immune-mediated platelet destruction. IVIG works by providing pooled antibodies to modulate the immune system and is typically employed in acute or severe cases to quickly improve platelet levels and prevent bleeding.

Therefore, all the factors stated above collectively will drive the overall plasma protein therapeutics market during the forecast period from 2024 to 2030.

However, stringent regulations for managing plasma protein products, and severe allergic reactions associated with the administration of plasma, among others may limit their end-user base, thus acting as key constraints limiting the growth of the plasma protein therapeutics.

Plasma Protein Therapeutics Market Segment Analysis:

Plasma Protein Therapeutics Market by Product (Immunoglobulin, Albumin, Plasma Derived Factor VIII, and Others), Application (Hemophilia, Idiopathic Thrombocytopenic, Primary Immunodeficiencies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the application segment of plasma protein therapeutics, the hemophilia category is expected to have a significant revenue share in the year 2023. The rapid growth of this product category can be attributed to the increased prevalence and awareness of hemophilia have led to the greater recognition and diagnosis of the condition.

This is further facilitated by advancements in genetic testing and screening technologies that enable earlier and more precise identification of the disorder. Continuous innovations in treatment options including the development of extended half-life clotting factors and recombinant therapies, have significantly improved treatment outcomes and patient compliance. These advancements not only enhance the effectiveness of therapies but also reduce the frequency of infusions, making them more convenient for patients.

Additionally, the growth of the application segment is anticipated to be driven by increasing research and development (R&D) activities and advancements by key companies. For example, in July 2021, Sanofi showcased new clinical data and research from its portfolio of marketed and investigational therapies for rare blood disorders, including hemophilia, immune thrombocytopenia (ITP), and acquired thrombotic thrombocytopenic purpura (aTTP).

Therefore, owing to all the above-mentioned factors, the demand for the hemophilia category upsurges, thereby the category is expected to witness considerable growth in the overall plasma protein therapeutics market.

North America is expected to dominate the overall plasma protein therapeutics market:

Among all the regions, North America is expected to dominate the plasma protein therapeutics market in the year 2023 and is expected to do the same during the forecast period. This is due to the increasing prevalence of conditions like Guillain-Barre Syndrome and the growing demand for effective treatments, coupled with strategic partnerships and regulatory advancements. The continuous development and approval of new plasma protein therapies are expected to significantly boost the market for plasma protein therapeutics in North America during the forecast period from 2024 to 2030.

According to data from the Centers of Disease Control and Prevention (2023), it stated that Guillain-Barre Syndrome (GBS) is a rare disorder in which the body's immune system mistakenly attacks the peripheral nerves. This damage to the nerves leads to muscle weakness and, in some cases, paralysis. The exact cause of GBS is not fully understood, but it frequently occurs following an infection with a virus or bacteria. In the United States, an estimated 3,000 to 6,000 people develop GBS each year. In GBS, plasma protein therapy, particularly intravenous immunoglobulin (IVIG), is used as a primary treatment. IVIG helps modulate the immune system by providing pooled antibodies from multiple donors, which can neutralize harmful antibodies attacking the peripheral nerves. This therapy reduces inflammation and supports nerve recovery, often leading to improved functional outcomes.

Various strategic partnerships and collaborations among biotech companies, pharmaceutical firms, and research institutions in North America are also expected to drive the market. For instance, in September 2022, Grifols announced that it signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.

Rising product developmental activities by regulatory bodies in the region will further boost the market for plasma protein therapeutics. For example, in June 2021, Kedrion Biopharma and Kamada Ltd., two leading biopharmaceutical companies specializing in plasma-derived protein therapeutics, announced that the U.S. Food and Drug Administration (FDA) approved a label update for KEDRAB(R) (Rabies Immune Globulin [Human]).

Therefore, the interplay of all the aforementioned factors is expected to provide a conducive growth environment for the North American plasma protein therapeutics market.

Plasma Protein Therapeutics Market key players:

Some of the key market players operating in the plasma protein therapeutics market include Octapharma AG, Takeda Pharmaceutical Company Limited, Biotest AG, Grifols, S.A., CSL, Bayer AG, Baxter, Bio Products Laboratory Ltd, Kedrion S.p.A, China Biologic Products Holdings, Inc, and others.

Recent Developmental Activities in the Plasma Protein Therapeutics Market:

• In March 2024, Biognosys, announced the release of enhanced plasma proteomics workflows for its TrueDiscovery(R) unbiased discovery proteomics research services platform. These new workflows utilize an innovative plasma enrichment method, providing comprehensive proteome coverage with outstanding data quality, reproducibility, and efficiency.
• In October 2022, Grifols inaugurated a new albumin purification and filling plant at its global manufacturing and supply hub in Dublin, Ireland. This milestone marked a significant advancement in the ongoing expansion of the site, which became increasingly crucial for the production, packaging, and distribution of Grifols therapies worldwide.

Key Takeaways from the Plasma Protein Therapeutics Market Report Study

• Market size analysis for current plasma protein therapeutics market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years.
• Key companies dominating the plasma protein therapeutics market
• Various opportunities available for the other competitors in the plasma protein therapeutics market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current plasma protein therapeutics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for plasma protein therapeutics market growth in the coming future?

Target audience who can be benefited from this Plasma Protein Therapeutics Market Report Study

• Plasma protein therapeutics product providers
• Research organizations and consulting companies
• Plasma protein therapeutics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in plasma protein therapeutics
• Various end-users who want to know more about the plasma protein therapeutics market and the latest developments in the plasma protein therapeutics market

Frequently Asked Questions for the Plasma Protein Therapeutics Market:

1. What are Plasma Protein Therapeutics?

Plasma protein therapeutics are biologic medications derived from human plasma, consisting of purified plasma proteins such as clotting factors, immunoglobulins, and albumin, used to treat specific deficiencies or dysfunctions of these proteins in various medical conditions.

2. What is the market for Plasma Protein Therapeutics?

The plasma protein therapeutics market was valued at USD 25.07 billion in 2023, growing at a CAGR of 6.65% during the forecast period from 2024 to 2030 to reach USD 39.27 billion by 2030.

3. What are the drivers for the Plasma Protein Therapeutics market?

The plasma protein therapeutics market is growing significantly due to the critical role plasma protein therapeutics play in managing diverse conditions such as hemophilia, multiple sclerosis, and immune thrombocytopenia by providing essential clotting factors, modulating immune responses, and improving patient outcomes. The ongoing advancements in these therapies and their expanding applications are expected to drive significant growth in the plasma protein therapeutics market from 2024 to 2030.

4. Who are the key players operating in the Plasma Protein Therapeutics market?

Some of the key market players operating in the plasma protein therapeutics market include Octapharma AG, Takeda Pharmaceutical Company Limited, Biotest AG, Grifols, S.A., CSL, Bayer AG, Baxter, Bio Products Laboratory Ltd, Kedrion S.p.A, China Biologic Products Holdings, Inc, and others.

5. Which region has the highest share in the Plasma Protein Therapeutics market?

Among all the regions, North America is estimated to hold a significant revenue share in the plasma protein therapeutics market. This can be ascribed to the increasing prevalence of conditions like Guillain-Barre Syndrome and the growing demand for effective treatments, coupled with strategic partnerships and regulatory advancements. The continuous development and approval of new plasma protein therapies are expected to significantly boost the market for plasma protein therapeutics in North America during the forecast period from 2024 to 2030.

Table of Contents

1. Plasma Protein Therapeutics Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Plasma Protein Therapeutics Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Plasma Protein Therapeutics Market Key Factors Analysis

• 5.1. Plasma Protein Therapeutics Market Drivers
  • 5.1.1. Rising cases of autoimmune and neurological disorders
  • 5.1.2. Increasing product developmental activities
  • 5.1.3. Strategic partnerships and collaborations among biotech companies, pharmaceutical firms, and research institutions
• 5.2. Plasma Protein Therapeutics Market Restraints and Challenges
  • 5.2.1. Stringent regulations for managing plasma protein products
  • 5.2.2. Severe allergic reactions associated with administration of plasma
• 5.3. Plasma Protein Therapeutics Market Opportunities
  • 5.3.1. Integrating plasma protein therapeutics into regenerative medicine

6. Plasma Protein Therapeutics Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Plasma Protein Therapeutics Market Assessment

• 7.1. By Product
  • 7.1.1. Immunoglobulin
  • 7.1.2. Albumin
  • 7.1.3. Plasma Derived Factor VIII
  • 7.1.4. Others
• 7.2. By Application
  • 7.2.1. Hemophilia
  • 7.2.2. Idiopathic Thrombocytopenic
  • 7.2.3. Primary Immunodeficiencies
  • 7.2.4. Others
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.1.2. Canada Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.1.3. Mexico Plasma Protein Therapeutics Market Size in USD million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.2.2. Germany Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.2.4. Italy Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.2.5. Spain Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.2.6. Rest of Europe Plasma Protein Therapeutics Market Size in USD million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.3.2. Japan Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.3.3. India Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.3.4. Australia Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.3.5. South Korea Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia-Pacific Plasma Protein Therapeutics Market Size in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.4.2. Africa Plasma Protein Therapeutics Market Size in USD million (2021-2030)
    • 7.3.4.3. South America Plasma Protein Therapeutics Market Size in USD million (2021-2030)

8. Plasma Protein Therapeutics Market Company and Product Profiles

• 8.1. Octapharma AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Takeda Pharmaceutical Company Limited
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Biotest AG
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Grifols, S.A.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. CSL
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Bayer AG
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Baxter
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Biologics, Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Bio Products Laboratory Ltd
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Kedrion S.p.A
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. China Biologic Products Holdings, Inc
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us